← Leaderboards

John Munn Kirkwood

University Of Pittsburgh At Pittsburgh

Google Scholar ↗PubMed ↗ORCID ↗

$15,450,309

Attributed

$22,566,494

Total exposure

29

Grants

13

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$55,883,077 · 31

By mechanism

P50$38,536,443 · 13

U10$7,827,210 · 2

UG1$6,597,164 · 1

R01$1,122,503 · 1

T32$973,122 · 1

R21$352,916 · 1

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Hassane M Zarour$16,372,397
Louis D Falo$30,012,458
Joanne L. Flynn$43,717,509
Graham F. Hatfull$17,993,179
Alicia R Mathers$4,373,803

Others in their field

Top investigators on “Melanoma”

David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
Richard L Schilsky · University Of Chicago$108,377,382
Larry Arthur$59,113,709
Charles A Coltman · Southwest Oncology Group$55,198,633
Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
Meenhard Herlyn · University Of Pennsylvania$46,448,742

Research focus

MelanomaClinical ResearchProgramsResearch PersonnelTranslational ResearchSkin CancerUniversity Of Pittsburgh Cancer InstituteFundingResourcesClinical TrialsUniversitiesInstitutionImmunotherapyEastern Cooperative Oncology GroupBasic ScienceCutaneous MelanomaServicesData ManagementEnsureInformaticsNeoplasm /Cancer ImmunotherapyBaseHuman SubjectTranslations

Grant awards (121)

Melanoma and Skin Cancer Program SPORE$2,217,934

P50 · FY2025 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$865,242

UG1 · FY2025 · CA

Project 5: Microenvironment manipulation using anti-angiogenics to improve immunotherapy in melanoma$276,920

P50 · FY2025 · CA

Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC)$50,414

P50 · FY2025 · CA

Melanoma and Skin Cancer Program SPORE$2,121,665

P50 · FY2024 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$936,542

UG1 · FY2024 · CA

Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC)$381,600

P50 · FY2024 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$200,000

UG1 · FY2024 · CA

Melanoma and Skin Cancer Program SPORE$1,974,834

P50 · FY2023 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076

UG1 · FY2023 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$40,000

UG1 · FY2023 · CA

Melanoma and Skin Cancer Program SPORE$2,070,180

P50 · FY2022 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076

UG1 · FY2022 · CA

Melanoma and Skin Cancer Program SPORE$2,037,632

P50 · FY2021 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076

UG1 · FY2021 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076

UG1 · FY2020 · CA

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076

UG1 · FY2019 · CA

Melanoma Program (Project-008)$34,500

P30 · FY2019 · CA · contact PI

NCI NCTN-Network Lead Academic Site at UPCI$898,424

U10 · FY2018 · CA

SPORE in Skin Cancer$500,000

P50 · FY2018 · CA · contact PI

Developmental Research Program$35,249

P50 · FY2018 · CA · contact PI

Melanoma Program (Project-008)$34,500

P30 · FY2018 · CA · contact PI

Training Program in Skin Biology and Cancer$28,920

T32 · FY2018 · CA · contact PI

Administrative Core$24,250

P50 · FY2018 · CA · contact PI

Melanoma Program (Project-008)$8,614

P30 · FY2018 · CA · contact PI

Melanoma Program (Project-008)$3,971

P30 · FY2018 · CA · contact PI

SPORE in Skin Cancer$2,350,000

P50 · FY2017 · CA · contact PI

NCI NCTN-Network Lead Academic Site at UPCI$898,445

U10 · FY2017 · CA

Administrative Core$262,047

P50 · FY2017 · CA · contact PI

Training Program in Skin Biology and Cancer$161,351

T32 · FY2017 · CA · contact PI

Developmental Research Program$74,906

P50 · FY2017 · CA · contact PI

Career Development Program$74,906

P50 · FY2017 · CA · contact PI

Melanoma Program (Project-008)$34,500

P30 · FY2017 · CA · contact PI

SPORE in Skin Cancer$2,162,000

P50 · FY2016 · CA · contact PI

NCI NCTN-Network Lead Academic Site at UPCI$853,523

U10 · FY2016 · CA

Training Program in Skin Biology and Cancer$301,575

T32 · FY2016 · CA · contact PI

Administrative Core$241,588

P50 · FY2016 · CA · contact PI

Career Development Program$65,925

P50 · FY2016 · CA · contact PI

Developmental Research Program$65,925

P50 · FY2016 · CA · contact PI

Melanoma Program (Project-008)$34,673

P30 · FY2016 · CA · contact PI

SPORE in Skin Cancer$2,185,000

P50 · FY2015 · CA · contact PI

NCI NCTN-Network Lead Academic Site at UPCI$898,445

U10 · FY2015 · CA

Training Program in Skin Biology and Cancer$313,708

T32 · FY2015 · CA · contact PI

Administrative Core$243,405

P50 · FY2015 · CA · contact PI

Career Development Program$66,421

P50 · FY2015 · CA · contact PI

Developmental Research Program$66,421

P50 · FY2015 · CA · contact PI

Melanoma Program (Project-008)$34,779

P30 · FY2015 · CA · contact PI

SPORE in Skin Cancer$2,161,838

P50 · FY2014 · CA · contact PI

NCI NCTN-Network Lead Academic Site at UPCI$945,732

U10 · FY2014 · CA

Administrative Core$247,744

P50 · FY2014 · CA · contact PI

Training Program in Skin Biology and Cancer$167,568

T32 · FY2014 · CA · contact PI

Developmental Research Program$23,238

P50 · FY2014 · CA · contact PI

Career Development Program$23,132

P50 · FY2014 · CA · contact PI

SPORE in Skin Cancer$2,150,500

P50 · FY2013 · CA · contact PI

Administrative Core$241,303

P50 · FY2013 · CA · contact PI

Eastern Cooperative Oncology Group (Main Institution)$200,536

U10 · FY2013 · CA · contact PI

Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane$187,072

R21 · FY2013 · CA · contact PI

Career Development Program$65,477

P50 · FY2013 · CA · contact PI

Developmental Research Program$65,477

P50 · FY2013 · CA · contact PI

SPORE in Skin Cancer$2,300,000

P50 · FY2012 · CA · contact PI

Administrative$307,275

P50 · FY2012 · CA · contact PI

Eastern Cooperative Oncology Group (Main Institution)$227,742

U10 · FY2012 · CA · contact PI

Immunologic & Genetic Determinants of Outcome & Response to IFN-a2b Therapy$180,804

P50 · FY2012 · CA · contact PI

Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane$165,844

R21 · FY2012 · CA · contact PI

Career Development Program$123,974

P50 · FY2012 · CA · contact PI

SPORE in Skin Cancer$2,185,000

P50 · FY2011 · CA · contact PI

Administrative$268,570

P50 · FY2011 · CA · contact PI

Eastern Cooperative Oncology Group (Main Institution)$187,319

U10 · FY2011 · CA · contact PI

Immunologic & Genetic Determinants of Outcome & Response to IFN-a2b Therapy$157,555

P50 · FY2011 · CA · contact PI

Career Development Program$107,425

P50 · FY2011 · CA · contact PI

SPORE in Skin Cancer$2,300,000

P50 · FY2010 · CA · contact PI

Administrative$282,815

P50 · FY2010 · CA · contact PI

Eastern Cooperative Oncology Group (Main Institution)$247,609

U10 · FY2010 · CA · contact PI

Immunologic & Genetic Determinants of Outcome & Response to IFN-a2b Therapy$169,083

P50 · FY2010 · CA · contact PI

Career Development Program$112,129

P50 · FY2010 · CA · contact PI

SPORE in Skin Cancer$2,300,000

P50 · FY2009 · CA · contact PI

Administrative$283,551

P50 · FY2009 · CA · contact PI

Eastern Cooporative Oncology Group (Main Institution)$250,100

U10 · FY2009 · CA · contact PI

Immunologic & Genetic Determinants of Outcome & Response to IFN-a2b Therapy$168,980

P50 · FY2009 · CA · contact PI

Career Development Program$111,412

P50 · FY2009 · CA · contact PI

SPORE in Skin Cancer$2,300,000

P50 · FY2008 · CA · contact PI

Eastern Cooporative Oncology Group (Main Institution)$243,642

U10 · FY2008 · CA · contact PI

Administrative$176,028

P50 · FY2008 · CA · contact PI

Immunologic & Genetic Determinants of Outcome & Response to IFN-a2b Therapy$104,848

P50 · FY2008 · CA · contact PI

Career Development Program$69,063

P50 · FY2008 · CA · contact PI

Eastern Cooporative Oncology Group (Main Institution)$244,813

U10 · FY2007 · CA · contact PI

Eastern Cooperative Oncology Gruop (Main Institution)$246,403

U10 · FY2006 · CA · contact PI

Eastern Cooperative Oncology Gruop (Main Institution)$244,098

U10 · FY2005 · CA

RANDOMIZED PLACEBO CONTROL PH3 TRIAL YEAST DERIVED GM-CSF VS PEPTIDE VACCINATIN$43,636

M01 · FY2005 · RR

PH1/II VACCINATION W/MELAN-A/MART-1 MULTI-EPITOPE CONT MELAN-A/MART PEPTIDES$36,308

M01 · FY2005 · RR

EVAL LOCAL GM-CSF ADJUVANT NUMBER VACCINE SITES IMMUNIZ W/MSMP$7,662

M01 · FY2005 · RR

RAND PH2 EVAL IMMUN AGST TUMOR CELLS PTS W/METAST MELANOMA DENDRITIC CELLS$1,999

M01 · FY2005 · RR

Eastern Cooperative Oncology Group (Main Institution)$241,494

U10 · FY2004 · CA

PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA$223,864

R01 · FY2004 · CA

PH1/II Vaccination with Melan-A/MART-1 Multi-Epitope$59,015

M01 · FY2004 · RR

PH3 Trial Yeast Derived GM-CSF vs. Peptide Vaccination$34,341

M01 · FY2004 · RR

PH2 HLA-A2 Multiepitope Peptide Vaccine &Tyrosinase$19,332

M01 · FY2004 · RR

Dendritic Cell Immunization for Metastatic Melanoma$1,272

M01 · FY2004 · RR

EASTERN COOPERATIVE ONCOLOGY GROUP$253,523

U10 · FY2003 · CA

PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA$224,618

R01 · FY2003 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP$254,385

U10 · FY2002 · CA

PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA$225,371

R01 · FY2002 · CA

PHASE III STUDY OF ADJUVANT GANGLIOSIDE VACCINATION VS INTERFERON THERAPY$0

M01 · FY2002 · RR

HIGH DOSE IFN ALFA 2B P450 ENZYME SYSTEM PTS W/ HIGH RISK MELANOMA$0

M01 · FY2002 · RR

HIGH DOSE IFN ALFA 2B P450 ENZYME SYSTEM PTS W/ HIGH RISK MELANOMA$0

M01 · FY2002 · RR

PHASE II TRIAL OF GM2 KHL/QS21 VACCINE WITH INTERFERON ALPHA 2B IN MELANOMA$0

M01 · FY2002 · RR

PHASE II TRIAL OF GM2 KHL/QS21 VACCINE WITH INTERFERON ALPHA 2B IN MELANOMA$0

M01 · FY2002 · RR

PHASE III STUDY OF ADJUVANT GANGLIOSIDE VACCINATION VS INTERFERON THERAPY$0

M01 · FY2002 · RR

EASTERN COOPERATIVE ONCOLOGY GROUP$249,117

U10 · FY2001 · CA

PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA$226,125

R01 · FY2001 · CA

PHASE III STUDY OF ADJUVANT GANGLIOSIDE VACCINATION VS INTERFERON THERAPY$0

M01 · FY2001 · RR

HIGH DOSE IFN ALFA 2B P450 ENZYME SYSTEM PTS W/ HIGH RISK MELANOMA$0

M01 · FY2001 · RR

PHASE II TRIAL OF GM2 KHL/QS21 VACCINE WITH INTERFERON ALPHA 2B IN MELANOMA$0

M01 · FY2001 · RR

EASTERN COOPERATIVE ONCOLOGY GROUP$241,860

U10 · FY2000 · CA

PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA$222,525

R01 · FY2000 · CA

BIOLOGIC THERAPY RESEARCH CAREER DEVELOPMENT PROGRAM$69,447

K12 · FY2000 · CA

PHASE III STUDY OF ADJUVANT GANGLIOSIDE VACCINATION VS INTERFERON THERAPY$3,034

M01 · FY2000 · RR

HIGH DOSE IFN ALFA 2B P450 ENZYME SYSTEM PTS W/ HIGH RISK MELANOMA$3,034

M01 · FY2000 · RR

PHASE II STUDY OF RHIL 12 IV INJECTIONS IN ADVANCED MALIGNANT MELANOMA PATIENTS$3,034

M01 · FY2000 · RR

PHASE II TRIAL OF GM2 KHL/QS21 VACCINE WITH INTERFERON ALPHA 2B IN MELANOMA$3,034

M01 · FY2000 · RR

MULTICENTER PILOT STUDY OF TUCARESOL IN METASTATIC MELANOMA$3,034

M01 · FY2000 · RR